These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 20886186)
1. Endocytic receptor for pro-coagulant factor VIII: relevance to inhibitor formation. Navarrete AM; Dasgupta S; Teyssandier M; Repesse Y; Delignat S; André S; Bayry J; Kaveri SV; Lacroix-Desmazes S Thromb Haemost; 2010 Dec; 104(6):1093-8. PubMed ID: 20886186 [TBL] [Abstract][Full Text] [Related]
2. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells. Kaveri SV; Dasgupta S; Andre S; Navarrete AM; Repessé Y; Wootla B; Lacroix-Desmazes S Haemophilia; 2007 Dec; 13 Suppl 5():61-4. PubMed ID: 18078399 [TBL] [Abstract][Full Text] [Related]
3. Dangerous liaisons: how the immune system deals with factor VIII. Wroblewska A; Reipert BM; Pratt KP; Voorberg J J Thromb Haemost; 2013 Jan; 11(1):47-55. PubMed ID: 23140211 [TBL] [Abstract][Full Text] [Related]
4. Immune response against serial infusion of factor VIII antigen through an implantable venous-access device system in haemophilia A mice. Madoiwa S; Kobayashi E; Kashiwakura Y; Sakata A; Yasumoto A; Ohmori T; Mimuro J; Sakata Y Haemophilia; 2012 May; 18(3):e323-30. PubMed ID: 22044430 [TBL] [Abstract][Full Text] [Related]
5. Requirements for immune recognition and processing of factor VIII by antigen-presenting cells. van Haren SD; Wroblewska A; Fischer K; Voorberg J; Herczenik E Blood Rev; 2012 Jan; 26(1):43-9. PubMed ID: 22036515 [TBL] [Abstract][Full Text] [Related]
7. von Willebrand factor and transforming growth factor-beta modulate immune response against coagulation factor VIII in FVIII-deficient mice. Kallas A; Kuuse S; Maimets T; Pooga M Thromb Res; 2007; 120(6):911-9. PubMed ID: 17376515 [TBL] [Abstract][Full Text] [Related]
8. Induction of tolerance to factor VIII by transient co-administration with rapamycin. Moghimi B; Sack BK; Nayak S; Markusic DM; Mah CS; Herzog RW J Thromb Haemost; 2011 Aug; 9(8):1524-33. PubMed ID: 21585650 [TBL] [Abstract][Full Text] [Related]
9. Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients. Hu G; Guo D; Key NS; Conti-Fine BM Thromb Haemost; 2007 May; 97(5):788-94. PubMed ID: 17479189 [TBL] [Abstract][Full Text] [Related]
10. Long-term tolerance to factor VIII is achieved by administration of interleukin-2/interleukin-2 monoclonal antibody complexes and low dosages of factor VIII. Liu CL; Ye P; Lin J; Djukovic D; Miao CH J Thromb Haemost; 2014 Jun; 12(6):921-31. PubMed ID: 24684505 [TBL] [Abstract][Full Text] [Related]
11. Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin. Biswas M; Rogers GL; Sherman A; Byrne BJ; Markusic DM; Jiang H; Herzog RW Thromb Haemost; 2017 Jan; 117(1):33-43. PubMed ID: 27683758 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors. Reipert BM; van Helden PM; Schwarz HP; Hausl C Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196 [TBL] [Abstract][Full Text] [Related]
13. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings. Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201 [TBL] [Abstract][Full Text] [Related]
14. The role of VWF in the immunogenicity of FVIII. Lacroix-Desmazes S; Repessé Y; Kaveri SV; Dasgupta S Thromb Res; 2008; 122 Suppl 2():S3-6. PubMed ID: 18549909 [TBL] [Abstract][Full Text] [Related]
15. Naturally occurring CD4+ CD25+ cells in modulating immune response to administered coagulation factor VIII in factor VIII-deficient mice. Kallas A; Kuuse S; Maimets T; Pooga M Haemophilia; 2011 Jan; 17(1):143-51. PubMed ID: 20731724 [TBL] [Abstract][Full Text] [Related]
16. Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects. Reding MT; Wu H; Krampf M; Okita DK; Diethelm-Okita BM; Christie BA; Key NS; Conti-Fine BM Thromb Haemost; 2000 Oct; 84(4):643-52. PubMed ID: 11057864 [TBL] [Abstract][Full Text] [Related]
18. Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients--long-term follow-up and continuing experience. Auerswald G; Bidlingmaier C; Kurnik K Haemophilia; 2012 Jan; 18(1):e18-20. PubMed ID: 21951822 [No Abstract] [Full Text] [Related]
19. Single cell analysis of factor VIII-specific T cells in hemophilic mice after treatment with human factor VIII. Sasgary M; Ahmad RU; Schwarz HP; Turecek PL; Reipert BM Thromb Haemost; 2002 Feb; 87(2):266-72. PubMed ID: 11858486 [TBL] [Abstract][Full Text] [Related]
20. Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A. Batty P; Moore GW; Platton S; Maloney JC; Palmer B; Bowles L; Pasi KJ; Rangarajan S; Hart DP Thromb Haemost; 2015 Oct; 114(4):804-11. PubMed ID: 26063073 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]